“The Molecular Taxonomy of Primary Prostate Cancer.” 2015. Cell 163 (4): 1011–25.

Adamo, P., and M. R. Ladomery. 2016. “The Oncogene ERG: A Key Factor in Prostate Cancer.” Oncogene 35 (4): 403–14.

Al Olama, Ali Amin, Zsofia Kote-Jarai, Sonja I. Berndt, David V. Conti, Fredrick Schumacher, Ying Han, Sara Benlloch, et al. 2014. “A Meta-Analysis of 87,040 Individuals Identifies 23 New Susceptibility Loci for Prostate Cancer.” Nature Genetics 46 (10): 1103–9.

Bostwick, David G., Deloar Hossain, JunqiI Qian, Roxann M. Neumann, Ping Yang, RobertT H. Young, P. Anthony Di sant’agnese, and Edward C. Jones. 2004. “PHYLLODES TUMOR OF THE PROSTATE: LONG-TERM FOLLOWUP STUDY OF 23 CASES.” The Journal of Urology 172 (3): 894–99.

Brunet, Anne, Sandeep Robert Datta, and Michael E Greenberg. 2001. “Transcription-Dependent and -Independent Control of Neuronal Survival by the PI3K–Akt Signaling Pathway.” Current Opinion in Neurobiology 11 (3): 297–305.

Cantley, Lewis C. 2002. “The Phosphoinositide 3-Kinase Pathway.” Science 296 (5573): 1655–57.

Cerveira, Nuno, Franclim R. Ribeiro, Ana Peixoto, Vera Costa, Rui Henrique, Carmen Jerönimo, and Manuel R. Teixeira. 2006. “TMPRSS2-ERG Gene Fusion Causing ERG Overexpression Precedes Chromosome Copy Number Changes in Prostate Carcinomas, Paired HGPIN Lesions.” Neoplasia 8 (10): 826–32.

De Angelis, Gabriela, Harry G Rittenhouse, Stephen D Mikolajczyk, L Blair Shamel, and Axel Semjonow. 2007. “Twenty Years of PSA: From Prostate Antigen to Tumor Marker.” Reviews in Urology 9 (3): 113–23.

Demichelis, F., K. Fall, S. Perner, O. Andrén, F. Schmidt, S. R. Setlur, Y. Hoshida, et al. 2007. “TMPRSS2:ERG Gene Fusion Associated with Lethal Prostate Cancer in a Watchful Waiting Cohort.” Oncogene 26 (31): 4596–99.

Deplus, Rachel, Carine Delliaux, Nathalie Marchand, Anne Flourens, Nathalie Vanpouille, Xavier Leroy, Yvan de Launoit, and Martine Duterque-Coquillaud. 2016. “TMPRSS2-ERG Fusion Promotes Prostate Cancer Metastases in Bone.” Oncotarget 8 (7): 11827–40.

Ferlay, Jacques, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Parkin, David Forman, and Freddie Bray. 2015. “Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012.” International Journal of Cancer 136 (5): E359–86.

Hermans, Karin G., Ronald van Marion, Herman van Dekken, Guido Jenster, Wytske M. van Weerden, and Jan Trapman. 2006. “TMPRSS2:ERG Fusion by Translocation or Interstitial Deletion Is Highly Relevant in Androgen-Dependent Prostate Cancer, But Is Bypassed in Late-Stage Androgen Receptor–Negative Prostate Cancer.” Cancer Research 66 (22): 10658–63.

Meller, Sebastian, Hellmuth-A. Meyer, Bianca Bethan, Dimo Dietrich, Sandra González Maldonado, Michael Lein, Matteo Montani, et al. 2016. “Integration of Tissue Metabolomics, Transcriptomics and Immunohistochemistry Reveals ERG- and Gleason Score-Specific Metabolomic Alterations in Prostate Cancer.” Oncotarget 7 (2): 1421–38.

Moniri, Mani Roshan-, Michael Hsing, Paul S. Rennie, Artem Cherkasov, and Michael E. Cox. 2017. “The Future of Prostate Cancer Precision Medicine: Anti-ERG Therapies.” Translational Cancer Research 6 (S7): S1136–38.

Peter, Anders, Hans Lilja, Åke Lundwall, and Johan Malm. 1998. “Semenogelin I and Semenogelin II, the Major Gel-Forming Proteins in Human Semen, Are Substrates for Transglutaminase.” European Journal of Biochemistry 252 (2): 216–21.

Perner, Sven, Francesca Demichelis, Rameen Beroukhim, Folke H. Schmidt, Juan-Miguel Mosquera, Sunita Setlur, Joelle Tchinda, et al. 2006. “TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer.” Cancer Research 66 (17): 8337–41.

Porter, Christopher R., Koichi Kodama, Robert P. Gibbons, Roy Correa, Felix K.-H. Chun, Paul Perrotte, and Pierre I. Karakiewicz. 2006. “25-Year Prostate Cancer Control and Survival Outcomes: A 40-Year Radical Prostatectomy Single Institution Series.” The Journal of Urology 176 (2): 569–74.

Tomlins, Scott A., Bharathi Laxman, Sooryanarayana Varambally, Xuhong Cao, Jindan Yu, Beth E. Helgeson, Qi Cao, et al. 2008. “Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer.” Neoplasia 10 (2): 177-IN9.

Tomlins, Scott A., Daniel R. Rhodes, Sven Perner, Saravana M. Dhanasekaran, Rohit Mehra, Xiao-Wei Sun, Sooryanarayana Varambally, et al. 2005. “Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer.” Science 310 (5748): 644–48.

Wang, M. C., L. A. Valenzuela, G. P. Murphy, and T. M. Chu. 1979. “Purification of a Human Prostate Specific Antigen.” Investigative Urology 17 (2): 159–63.

Wang, Xiaoju, Yuanyuan Qiao, Irfan A. Asangani, Bushra Ateeq, Anton Poliakov, Marcin Cieślik, Sethuramasundaram Pitchiaya, et al. 2017. “Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.” Cancer Cell 31 (4): 532-548.e7.

Wang, Xiaoju, Yuanyuan Qiao, Irfan A. Asangani, Bushra Ateeq, Anton Poliakov, Marcin Cieślik, Sethuramasundaram Pitchiaya, et al. 2017. “Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.” Cancer Cell 31 (4): 532-548.e7.

Yu, Jindan, Jianjun Yu, Ram-Shankar Mani, Qi Cao, Chad J. Brenner, Xuhong Cao, George X. Wang, et al. 2010. “An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression.” Cancer Cell 17 (5): 443–54.

Zong, Yang, Li Xin, Andrew S. Goldstein, Devon A. Lawson, Michael A. Teitell, and Owen N. Witte. 2009. “ETS Family Transcription Factors Collaborate with Alternative Signaling Pathways to Induce Carcinoma from Adult Murine Prostate Cells.” Proceedings of the National Academy of Sciences of the United States of America 106 (30): 12465–70.


Leave a Reply

Your email address will not be published. Required fields are marked *